The primary target of our enterprise is to develop vaccines and therapeutic products for infectious diseases and cancer. We are developing safe and effective delivery platforms including epitope, surface display, mRNA and dendritic cell-based vaccine utilizing cutting-edge computational biology, in vitro and in vivo studies.
Moreover, Vaxigen is developing and scaling up a proprietary, novel, and cost-effective cell culture medium as well as a cell storage medium that can be frozen without deleterious effects on the cells. We are carrying out an array of in vitro assays under contract and consultancy project basis. Our state-of-art instrumentation facility offers researchers and students to carry out part of their research at Vaxigen International Research Center.